Cargando…

A Novel Prognostic Signature of Transcription Factors for the Prediction in Patients With GBM

Background: Although the diagnosis and treatment of glioblastoma (GBM) is significantly improved with recent progresses, there is still a large heterogeneity in therapeutic effects and overall survival. The aim of this study is to analyze gene expressions of transcription factors (TFs) in GBM so as...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheng, Quan, Huang, Chunhai, Cao, Hui, Lin, Jinhu, Gong, Xuan, Li, Jian, Chen, Yuanbing, Tian, Zhi, Fang, Zhenyu, Huang, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6779830/
https://www.ncbi.nlm.nih.gov/pubmed/31632439
http://dx.doi.org/10.3389/fgene.2019.00906
_version_ 1783456982931341312
author Cheng, Quan
Huang, Chunhai
Cao, Hui
Lin, Jinhu
Gong, Xuan
Li, Jian
Chen, Yuanbing
Tian, Zhi
Fang, Zhenyu
Huang, Jun
author_facet Cheng, Quan
Huang, Chunhai
Cao, Hui
Lin, Jinhu
Gong, Xuan
Li, Jian
Chen, Yuanbing
Tian, Zhi
Fang, Zhenyu
Huang, Jun
author_sort Cheng, Quan
collection PubMed
description Background: Although the diagnosis and treatment of glioblastoma (GBM) is significantly improved with recent progresses, there is still a large heterogeneity in therapeutic effects and overall survival. The aim of this study is to analyze gene expressions of transcription factors (TFs) in GBM so as to discover new tumor markers. Methods: Differentially expressed TFs are identified by data mining using public databases. The GBM transcriptome profile is downloaded from The Cancer Genome Atlas (TCGA). The nonnegative matrix factorization (NMF) method is used to cluster the differentially expressed genes to discover hub genes and signal pathways. The TFs affecting the prognosis of GBM are screened by univariate and multivariate COX regression analysis, and the receiver operating characteristic (ROC) curve is determined. The GBM hazard model and nomogram map are constructed by integrating the clinical data. Finally, the TFs involving potential signaling pathways in GBM are screened by Gene Set Enrichment Analysis (GSEA), Gene Ontology (GO), and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis. Results: There are 68 differentially expressed TFs in GBM, of which 43 genes are upregulated and 25 genes are downregulated. NMF clustering analysis suggested that GBM patients are divided into three groups: Clusters A, B, and C. LHX2, MEOX2, SNAI2, and ZNF22 are identified from the above differential genes by univariate/multivariate regression analysis. The risk score of those four genes are calculated based on the beta coefficient of each gene, and we found that the predictive ability of the risk score gradually increased with the prolonged predicted termination time by time-dependent ROC curve analysis. The nomogram results have showed that the integration of risk score, age, gender, chemotherapy, radiotherapy, and 1p/19q can further improve predictive ability towards the survival of GBM. The pathways in cancer, phosphoinositide 3-kinases (PI3K)–Akt signaling, Hippo signaling, and proteoglycans, are highly enriched in high-risk groups by GSEA. These genes are mainly involved in cell migration, cell adhesion, epithelial–mesenchymal transition (EMT), cell cycle, and other signaling pathways by GO and KEGG analysis. Conclusion: The four-factor combined scoring model of LHX2, MEOX2, SNAI2, and ZNF22 can precisely predict the prognosis of patients with GBM.
format Online
Article
Text
id pubmed-6779830
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-67798302019-10-18 A Novel Prognostic Signature of Transcription Factors for the Prediction in Patients With GBM Cheng, Quan Huang, Chunhai Cao, Hui Lin, Jinhu Gong, Xuan Li, Jian Chen, Yuanbing Tian, Zhi Fang, Zhenyu Huang, Jun Front Genet Genetics Background: Although the diagnosis and treatment of glioblastoma (GBM) is significantly improved with recent progresses, there is still a large heterogeneity in therapeutic effects and overall survival. The aim of this study is to analyze gene expressions of transcription factors (TFs) in GBM so as to discover new tumor markers. Methods: Differentially expressed TFs are identified by data mining using public databases. The GBM transcriptome profile is downloaded from The Cancer Genome Atlas (TCGA). The nonnegative matrix factorization (NMF) method is used to cluster the differentially expressed genes to discover hub genes and signal pathways. The TFs affecting the prognosis of GBM are screened by univariate and multivariate COX regression analysis, and the receiver operating characteristic (ROC) curve is determined. The GBM hazard model and nomogram map are constructed by integrating the clinical data. Finally, the TFs involving potential signaling pathways in GBM are screened by Gene Set Enrichment Analysis (GSEA), Gene Ontology (GO), and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis. Results: There are 68 differentially expressed TFs in GBM, of which 43 genes are upregulated and 25 genes are downregulated. NMF clustering analysis suggested that GBM patients are divided into three groups: Clusters A, B, and C. LHX2, MEOX2, SNAI2, and ZNF22 are identified from the above differential genes by univariate/multivariate regression analysis. The risk score of those four genes are calculated based on the beta coefficient of each gene, and we found that the predictive ability of the risk score gradually increased with the prolonged predicted termination time by time-dependent ROC curve analysis. The nomogram results have showed that the integration of risk score, age, gender, chemotherapy, radiotherapy, and 1p/19q can further improve predictive ability towards the survival of GBM. The pathways in cancer, phosphoinositide 3-kinases (PI3K)–Akt signaling, Hippo signaling, and proteoglycans, are highly enriched in high-risk groups by GSEA. These genes are mainly involved in cell migration, cell adhesion, epithelial–mesenchymal transition (EMT), cell cycle, and other signaling pathways by GO and KEGG analysis. Conclusion: The four-factor combined scoring model of LHX2, MEOX2, SNAI2, and ZNF22 can precisely predict the prognosis of patients with GBM. Frontiers Media S.A. 2019-10-01 /pmc/articles/PMC6779830/ /pubmed/31632439 http://dx.doi.org/10.3389/fgene.2019.00906 Text en Copyright © 2019 Cheng, Huang, Cao, Lin, Gong, Li, Chen, Tian, Fang and Huang http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Genetics
Cheng, Quan
Huang, Chunhai
Cao, Hui
Lin, Jinhu
Gong, Xuan
Li, Jian
Chen, Yuanbing
Tian, Zhi
Fang, Zhenyu
Huang, Jun
A Novel Prognostic Signature of Transcription Factors for the Prediction in Patients With GBM
title A Novel Prognostic Signature of Transcription Factors for the Prediction in Patients With GBM
title_full A Novel Prognostic Signature of Transcription Factors for the Prediction in Patients With GBM
title_fullStr A Novel Prognostic Signature of Transcription Factors for the Prediction in Patients With GBM
title_full_unstemmed A Novel Prognostic Signature of Transcription Factors for the Prediction in Patients With GBM
title_short A Novel Prognostic Signature of Transcription Factors for the Prediction in Patients With GBM
title_sort novel prognostic signature of transcription factors for the prediction in patients with gbm
topic Genetics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6779830/
https://www.ncbi.nlm.nih.gov/pubmed/31632439
http://dx.doi.org/10.3389/fgene.2019.00906
work_keys_str_mv AT chengquan anovelprognosticsignatureoftranscriptionfactorsforthepredictioninpatientswithgbm
AT huangchunhai anovelprognosticsignatureoftranscriptionfactorsforthepredictioninpatientswithgbm
AT caohui anovelprognosticsignatureoftranscriptionfactorsforthepredictioninpatientswithgbm
AT linjinhu anovelprognosticsignatureoftranscriptionfactorsforthepredictioninpatientswithgbm
AT gongxuan anovelprognosticsignatureoftranscriptionfactorsforthepredictioninpatientswithgbm
AT lijian anovelprognosticsignatureoftranscriptionfactorsforthepredictioninpatientswithgbm
AT chenyuanbing anovelprognosticsignatureoftranscriptionfactorsforthepredictioninpatientswithgbm
AT tianzhi anovelprognosticsignatureoftranscriptionfactorsforthepredictioninpatientswithgbm
AT fangzhenyu anovelprognosticsignatureoftranscriptionfactorsforthepredictioninpatientswithgbm
AT huangjun anovelprognosticsignatureoftranscriptionfactorsforthepredictioninpatientswithgbm
AT chengquan novelprognosticsignatureoftranscriptionfactorsforthepredictioninpatientswithgbm
AT huangchunhai novelprognosticsignatureoftranscriptionfactorsforthepredictioninpatientswithgbm
AT caohui novelprognosticsignatureoftranscriptionfactorsforthepredictioninpatientswithgbm
AT linjinhu novelprognosticsignatureoftranscriptionfactorsforthepredictioninpatientswithgbm
AT gongxuan novelprognosticsignatureoftranscriptionfactorsforthepredictioninpatientswithgbm
AT lijian novelprognosticsignatureoftranscriptionfactorsforthepredictioninpatientswithgbm
AT chenyuanbing novelprognosticsignatureoftranscriptionfactorsforthepredictioninpatientswithgbm
AT tianzhi novelprognosticsignatureoftranscriptionfactorsforthepredictioninpatientswithgbm
AT fangzhenyu novelprognosticsignatureoftranscriptionfactorsforthepredictioninpatientswithgbm
AT huangjun novelprognosticsignatureoftranscriptionfactorsforthepredictioninpatientswithgbm